title: Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line.
abstract: BACKGROUND
  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in tumor cells, but when used alone, it is not effective in the treatment of TRAIL-resistant tumors. Some studies have shown that gefitinib interacts with recombinant mutant human TRAIL (rmhTRAIL) to induce high levels of apoptosis in gefitinib-responsive bladder cancer cell lines; however, the molecular mechanisms underlying the anticancer effects are not fully understood. Several reports have shown that the death receptor 5 (DR5) plays an important role in sensitizing cancer cells to apoptosis induced by TRAIL. Therefore, we investigated the effects of the combination of drugs and the expression of the DR5 to analyze the growth of a gefitinib-responsive non-small cell lung cancer cell line PC9, which was treated with rmhTRAIL and gefitinib individually or in combination.
  
  
  METHODS
  Human PC9 non-small cell lung cancer cells harboring an epidermal growth factor receptor mutation were used as a model for the identification of the therapeutic effects of gefitinib alone or in combination with rmhTRAIL, and cytotoxicity was assessed by MTT assays. Cell cycle and apoptosis were investigated using flow cytometry. Moreover, the effects of drugs on DR5, BAX, FLIP, and cleaved-caspase3 proteins expressions were analyzed using Western blot analyses. Finally, quantitative polymerase chain reaction analysis was carried out to assess whether rmhTRAIL and gefitinib modulate the expression of genes related to drug activity.
  
  
  RESULTS
  Gefitinib and rmhTRAIL synergistically interact to inhibit cell proliferation, and apoptosis assessment demonstrated that associations of drug increased the apoptotic index. rmhTRAIL when used alone downregulated DR5 and upregulated BAX, FLIP, and cleaved-caspase3 proteins expressions. However, results obtained in Western blot analyses demonstrated that the combined treatment-induced cell apoptosis was achieved involving upregulated DR5, cleaved-caspase3, and BAX proteins expression and downregulated FLIP protein expression. Moreover, quantitative polymerase chain reaction showed that gefitinib modulated the expression of targets related to rmhTRAIL activity.
  
  
  CONCLUSIONS
  These results indicate that epidermal growth factor receptor inhibitors enhance rmhTRAIL antitumor activity in the gefitinib-responsive PC9 cell line, and upregulated DR5 expression plays a critical role in activating caspase-signaling apoptotic pathway.
authors.affiliation: Department of Oncology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, People's Republic of China ; Translational Molecular pathology, M.D Anderson Cancer Center, Houston, TX, USA.
authors.forename: Dong
authors.initials: D
authors.lastname: Yan
authors.affiliation: Department of Oncology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, People's Republic of China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Ge
authors.affiliation: School of Sciences, Tsinghua University, Beijing, People's Republic of China.
authors.forename: Haiteng
authors.initials: H
authors.lastname: Deng
authors.affiliation: Department of Hematology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, People's Republic of China.
authors.forename: Wenming
authors.initials: W
authors.lastname: Chen
authors.affiliation: Department of Oncology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, People's Republic of China.
authors.forename: Guangyu
authors.initials: G
authors.lastname: An
keywords: DR5; apoptosis; gefitinib; rmhTRAIL